Penumbra, Inc. (NYSE: PEN) Stock Competitors & Peer Comparison
See PEN's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for PEN and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PEN | $321.68 | +0.21% | 12.7B | 84.03 | $3.83 | N/A |
| ABT | $112.47 | +0.79% | 194.6B | 21.58 | $5.21 | +2.21% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| SYK | $330.69 | +2.66% | 126.8B | 24.70 | $13.39 | +1.05% |
| MDT | $91.23 | +1.40% | 116.7B | 16.49 | $5.53 | +3.12% |
| BSX | $46.84 | +0.36% | 69.6B | 15.11 | $3.10 | N/A |
| EW | $90.21 | +0.29% | 51.9B | 33.41 | $2.70 | N/A |
| DXCM | $90.82 | +1.71% | 34.3B | 35.62 | $2.55 | N/A |
| GEHC | $71.72 | -1.05% | 32.4B | 15.73 | $4.56 | +0.19% |
| PHG | $26.72 | -0.74% | 26.1B | 15.26 | $1.75 | +3.71% |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
PEN vs ABT Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, ABT has a market cap of 194.6B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while ABT trades at $112.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas ABT's P/E ratio is 21.58. In terms of profitability, PEN's ROE is +0.11%, compared to ABT's ROE of +0.11%. Regarding short-term risk, PEN is less volatile compared to ABT. This indicates lower risk in terms of short-term price fluctuations for PEN.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
PEN vs BSX-PA Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, PEN's ROE is +0.11%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, PEN is less volatile compared to BSX-PA. This indicates lower risk in terms of short-term price fluctuations for PEN.Check BSX-PA's competition here
Stryker Corporation (NYSE: SYK)
PEN vs SYK Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, SYK has a market cap of 126.8B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while SYK trades at $330.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas SYK's P/E ratio is 24.70. In terms of profitability, PEN's ROE is +0.11%, compared to SYK's ROE of +0.16%. Regarding short-term risk, PEN is less volatile compared to SYK. This indicates lower risk in terms of short-term price fluctuations for PEN.Check SYK's competition here
Medtronic plc (NYSE: MDT)
PEN vs MDT Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, MDT has a market cap of 116.7B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while MDT trades at $91.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas MDT's P/E ratio is 16.49. In terms of profitability, PEN's ROE is +0.11%, compared to MDT's ROE of +0.10%. Regarding short-term risk, PEN is less volatile compared to MDT. This indicates lower risk in terms of short-term price fluctuations for PEN.Check MDT's competition here
Boston Scientific Corporation (NYSE: BSX)
PEN vs BSX Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, BSX has a market cap of 69.6B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while BSX trades at $46.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas BSX's P/E ratio is 15.11. In terms of profitability, PEN's ROE is +0.11%, compared to BSX's ROE of +0.15%. Regarding short-term risk, PEN is less volatile compared to BSX. This indicates lower risk in terms of short-term price fluctuations for PEN.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
PEN vs EW Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, EW has a market cap of 51.9B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while EW trades at $90.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas EW's P/E ratio is 33.41. In terms of profitability, PEN's ROE is +0.11%, compared to EW's ROE of +0.10%. Regarding short-term risk, PEN is less volatile compared to EW. This indicates lower risk in terms of short-term price fluctuations for PEN.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
PEN vs DXCM Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, DXCM has a market cap of 34.3B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while DXCM trades at $90.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas DXCM's P/E ratio is 35.62. In terms of profitability, PEN's ROE is +0.11%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, PEN is less volatile compared to DXCM. This indicates lower risk in terms of short-term price fluctuations for PEN.Check DXCM's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
PEN vs GEHC Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, GEHC has a market cap of 32.4B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while GEHC trades at $71.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas GEHC's P/E ratio is 15.73. In terms of profitability, PEN's ROE is +0.11%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, PEN is less volatile compared to GEHC. This indicates lower risk in terms of short-term price fluctuations for PEN.Check GEHC's competition here
Koninklijke Philips N.V. (NYSE: PHG)
PEN vs PHG Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, PHG has a market cap of 26.1B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while PHG trades at $26.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas PHG's P/E ratio is 15.26. In terms of profitability, PEN's ROE is +0.11%, compared to PHG's ROE of +0.10%. Regarding short-term risk, PEN is less volatile compared to PHG. This indicates lower risk in terms of short-term price fluctuations for PEN.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
PEN vs ZBH Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, ZBH has a market cap of 19.5B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while ZBH trades at $100.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas ZBH's P/E ratio is 11.90. In terms of profitability, PEN's ROE is +0.11%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, PEN is less volatile compared to ZBH. This indicates lower risk in terms of short-term price fluctuations for PEN.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
PEN vs ABMD Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas ABMD's P/E ratio is 65.36. In terms of profitability, PEN's ROE is +0.11%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, PEN is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for PEN.Check ABMD's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
PEN vs SWAV Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas SWAV's P/E ratio is 78.76. In terms of profitability, PEN's ROE is +0.11%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, PEN is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for PEN.Check SWAV's competition here
Smith & Nephew plc (NYSE: SNN)
PEN vs SNN Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, SNN has a market cap of 12.2B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while SNN trades at $28.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas SNN's P/E ratio is 13.64. In terms of profitability, PEN's ROE is +0.11%, compared to SNN's ROE of +0.12%. Regarding short-term risk, PEN is less volatile compared to SNN. This indicates lower risk in terms of short-term price fluctuations for PEN.Check SNN's competition here
Align Technology, Inc. (NASDAQ: ALGN)
PEN vs ALGN Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, ALGN has a market cap of 11.3B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while ALGN trades at $157.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas ALGN's P/E ratio is 14.36. In terms of profitability, PEN's ROE is +0.11%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, PEN is less volatile compared to ALGN. This indicates lower risk in terms of short-term price fluctuations for PEN.Check ALGN's competition here
Globus Medical, Inc. (NYSE: GMED)
PEN vs GMED Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, GMED has a market cap of 11.2B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while GMED trades at $82.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas GMED's P/E ratio is 18.69. In terms of profitability, PEN's ROE is +0.11%, compared to GMED's ROE of +0.12%. Regarding short-term risk, PEN is less volatile compared to GMED. This indicates lower risk in terms of short-term price fluctuations for PEN.Check GMED's competition here
Glaukos Corporation (NYSE: GKOS)
PEN vs GKOS Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, GKOS has a market cap of 10.6B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while GKOS trades at $179.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas GKOS's P/E ratio is -209.16. In terms of profitability, PEN's ROE is +0.11%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, PEN is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for PEN.Check GKOS's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
PEN vs BIO-B Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, BIO-B has a market cap of 10.6B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while BIO-B trades at $387.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas BIO-B's P/E ratio is -68.15. In terms of profitability, PEN's ROE is +0.11%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, PEN is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for PEN.Check BIO-B's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
PEN vs BIO Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, BIO has a market cap of 10.4B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while BIO trades at $387.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas BIO's P/E ratio is 41.79. In terms of profitability, PEN's ROE is +0.11%, compared to BIO's ROE of +0.03%. Regarding short-term risk, PEN is less volatile compared to BIO. This indicates lower risk in terms of short-term price fluctuations for PEN.Check BIO's competition here
Insulet Corp. (NASDAQ: PODD)
PEN vs PODD Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, PODD has a market cap of 10.1B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while PODD trades at $145.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas PODD's P/E ratio is 24.72. In terms of profitability, PEN's ROE is +0.11%, compared to PODD's ROE of +0.27%. Regarding short-term risk, PEN is less volatile compared to PODD. This indicates lower risk in terms of short-term price fluctuations for PEN.Check PODD's competition here
Masimo Corporation (NASDAQ: MASI)
PEN vs MASI Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas MASI's P/E ratio is 44.43. In terms of profitability, PEN's ROE is +0.11%, compared to MASI's ROE of +0.09%. Regarding short-term risk, PEN is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for PEN.Check MASI's competition here
Bruker Corporation (NASDAQ: BRKR)
PEN vs BRKR Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, BRKR has a market cap of 8.7B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while BRKR trades at $57.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas BRKR's P/E ratio is 28.68. In terms of profitability, PEN's ROE is +0.11%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, PEN is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for PEN.Check BRKR's competition here
Bruker Corporation (NASDAQ: BRKRP)
PEN vs BRKRP Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, BRKRP has a market cap of 8.5B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while BRKRP trades at $420.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas BRKRP's P/E ratio is 229.28. In terms of profitability, PEN's ROE is +0.11%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, PEN is less volatile compared to BRKRP. This indicates lower risk in terms of short-term price fluctuations for PEN.Check BRKRP's competition here
Haemonetics Corporation (NYSE: HAE)
PEN vs HAE Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, HAE has a market cap of 4.7B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while HAE trades at $103.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas HAE's P/E ratio is 20.74. In terms of profitability, PEN's ROE is +0.11%, compared to HAE's ROE of +0.11%. Regarding short-term risk, PEN is less volatile compared to HAE. This indicates lower risk in terms of short-term price fluctuations for PEN.Check HAE's competition here
Inari Medical, Inc. (NASDAQ: NARI)
PEN vs NARI Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas NARI's P/E ratio is -59.24. In terms of profitability, PEN's ROE is +0.11%, compared to NARI's ROE of -0.00%. Regarding short-term risk, PEN is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for PEN.Check NARI's competition here
LivaNova PLC (NASDAQ: LIVN)
PEN vs LIVN Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, LIVN has a market cap of 4.4B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while LIVN trades at $80.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas LIVN's P/E ratio is 19.08. In terms of profitability, PEN's ROE is +0.11%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, PEN is less volatile compared to LIVN. This indicates lower risk in terms of short-term price fluctuations for PEN.Check LIVN's competition here
Integer Holdings Corporation (NYSE: ITGR)
PEN vs ITGR Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while ITGR trades at $125.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas ITGR's P/E ratio is 19.73. In terms of profitability, PEN's ROE is +0.11%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, PEN is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for PEN.Check ITGR's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
PEN vs IRTC Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, IRTC has a market cap of 3.8B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while IRTC trades at $120.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas IRTC's P/E ratio is -270.53. In terms of profitability, PEN's ROE is +0.11%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, PEN is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for PEN.Check IRTC's competition here
Axonics, Inc. (NASDAQ: AXNX)
PEN vs AXNX Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas AXNX's P/E ratio is -709.80. In terms of profitability, PEN's ROE is +0.11%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, PEN is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for PEN.Check AXNX's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
PEN vs TMDX Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, TMDX has a market cap of 3.1B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while TMDX trades at $88.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas TMDX's P/E ratio is 44.89. In terms of profitability, PEN's ROE is +0.11%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, PEN is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for PEN.Check TMDX's competition here
AxoGen, Inc. (NASDAQ: AXGN)
PEN vs AXGN Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, AXGN has a market cap of 2.8B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while AXGN trades at $51.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas AXGN's P/E ratio is 135.45. In terms of profitability, PEN's ROE is +0.11%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, PEN is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for PEN.Check AXGN's competition here
Neogen Corporation (NASDAQ: NEOG)
PEN vs NEOG Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, NEOG has a market cap of 2.5B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while NEOG trades at $11.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas NEOG's P/E ratio is 41.64. In terms of profitability, PEN's ROE is +0.11%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, PEN is less volatile compared to NEOG. This indicates lower risk in terms of short-term price fluctuations for PEN.Check NEOG's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
PEN vs UFPT Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, UFPT has a market cap of 2.3B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while UFPT trades at $300.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas UFPT's P/E ratio is 30.65. In terms of profitability, PEN's ROE is +0.11%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, PEN is less volatile compared to UFPT. This indicates lower risk in terms of short-term price fluctuations for PEN.Check UFPT's competition here
Butterfly Network, Inc. (NYSE: BFLY)
PEN vs BFLY Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, BFLY has a market cap of 2.2B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while BFLY trades at $8.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas BFLY's P/E ratio is -35.12. In terms of profitability, PEN's ROE is +0.11%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, PEN is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for PEN.Check BFLY's competition here
NuVasive, Inc. (NASDAQ: NUVA)
PEN vs NUVA Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas NUVA's P/E ratio is 75.00. In terms of profitability, PEN's ROE is +0.11%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, PEN is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for PEN.Check NUVA's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
PEN vs ESTA Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, ESTA has a market cap of 2.1B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while ESTA trades at $70.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas ESTA's P/E ratio is -56.06. In terms of profitability, PEN's ROE is +0.11%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, PEN is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for PEN.Check ESTA's competition here
Novocure Ltd (NASDAQ: NVCR)
PEN vs NVCR Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, NVCR has a market cap of 2.1B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while NVCR trades at $17.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas NVCR's P/E ratio is -13.71. In terms of profitability, PEN's ROE is +0.11%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, PEN is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for PEN.Check NVCR's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
PEN vs INSP Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, INSP has a market cap of 1.8B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while INSP trades at $61.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas INSP's P/E ratio is 27.10. In terms of profitability, PEN's ROE is +0.11%, compared to INSP's ROE of +0.18%. Regarding short-term risk, PEN is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for PEN.Check INSP's competition here
CONMED Corporation (NYSE: CNMD)
PEN vs CNMD Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while CNMD trades at $49.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas CNMD's P/E ratio is 11.00. In terms of profitability, PEN's ROE is +0.11%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, PEN is less volatile compared to CNMD. This indicates lower risk in terms of short-term price fluctuations for PEN.Check CNMD's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
PEN vs TNDM Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, TNDM has a market cap of 1.5B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while TNDM trades at $21.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas TNDM's P/E ratio is -23.04. In terms of profitability, PEN's ROE is +0.11%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, PEN is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for PEN.Check TNDM's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
PEN vs ATEC Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, ATEC has a market cap of 1.5B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while ATEC trades at $9.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas ATEC's P/E ratio is -157.33. In terms of profitability, PEN's ROE is +0.11%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, PEN is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for PEN.Check ATEC's competition here
Enovis Corporation (NYSE: ENOV)
PEN vs ENOV Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, ENOV has a market cap of 1.4B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while ENOV trades at $24.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas ENOV's P/E ratio is 7.13. In terms of profitability, PEN's ROE is +0.11%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, PEN is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for PEN.Check ENOV's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
PEN vs IART Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while IART trades at $16.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas IART's P/E ratio is 7.16. In terms of profitability, PEN's ROE is +0.11%, compared to IART's ROE of -0.01%. Regarding short-term risk, PEN is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for PEN.Check IART's competition here
Heska Corporation (NASDAQ: HSKA)
PEN vs HSKA Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas HSKA's P/E ratio is -62.49. In terms of profitability, PEN's ROE is +0.11%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, PEN is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for PEN.Check HSKA's competition here
Artivion, Inc. (NYSE: AORT)
PEN vs AORT Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, AORT has a market cap of 1.3B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while AORT trades at $26.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas AORT's P/E ratio is 44.57. In terms of profitability, PEN's ROE is +0.11%, compared to AORT's ROE of -0.01%. Regarding short-term risk, PEN is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for PEN.Check AORT's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
PEN vs PRCT Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, PRCT has a market cap of 1.2B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while PRCT trades at $20.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas PRCT's P/E ratio is -10.74. In terms of profitability, PEN's ROE is +0.11%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, PEN is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for PEN.Check PRCT's competition here
Avanos Medical, Inc. (NYSE: AVNS)
PEN vs AVNS Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas AVNS's P/E ratio is 27.77. In terms of profitability, PEN's ROE is +0.11%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, PEN is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for PEN.Check AVNS's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
PEN vs SILK Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas SILK's P/E ratio is -18.96. In terms of profitability, PEN's ROE is +0.11%, compared to SILK's ROE of -0.35%. Regarding short-term risk, PEN is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for PEN.Check SILK's competition here
IRadimed Corporation (NASDAQ: IRMD)
PEN vs IRMD Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while IRMD trades at $87.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas IRMD's P/E ratio is 43.75. In terms of profitability, PEN's ROE is +0.11%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, PEN is less volatile compared to IRMD. This indicates lower risk in terms of short-term price fluctuations for PEN.Check IRMD's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
PEN vs LMRI Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while LMRI trades at $11.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas LMRI's P/E ratio is -22.39. In terms of profitability, PEN's ROE is +0.11%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, PEN is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for PEN.Check LMRI's competition here
Paragon 28, Inc. (NYSE: FNA)
PEN vs FNA Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas FNA's P/E ratio is -19.83. In terms of profitability, PEN's ROE is +0.11%, compared to FNA's ROE of -0.35%. Regarding short-term risk, PEN is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for PEN.Check FNA's competition here
Bioventus Inc. (NASDAQ: BVS)
PEN vs BVS Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, BVS has a market cap of 937.6M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while BVS trades at $13.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas BVS's P/E ratio is 18.21. In terms of profitability, PEN's ROE is +0.11%, compared to BVS's ROE of +0.28%. Regarding short-term risk, PEN is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for PEN.Check BVS's competition here
CeriBell, Inc. (NASDAQ: CBLL)
PEN vs CBLL Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, CBLL has a market cap of 900.4M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while CBLL trades at $23.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas CBLL's P/E ratio is -13.48. In terms of profitability, PEN's ROE is +0.11%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, PEN is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for PEN.Check CBLL's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
PEN vs BBNX Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, BBNX has a market cap of 887.2M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while BBNX trades at $19.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas BBNX's P/E ratio is -11.95. In terms of profitability, PEN's ROE is +0.11%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, PEN is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for PEN.Check BBNX's competition here
InMode Ltd. (NASDAQ: INMD)
PEN vs INMD Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, INMD has a market cap of 853.6M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while INMD trades at $14.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas INMD's P/E ratio is 10.31. In terms of profitability, PEN's ROE is +0.11%, compared to INMD's ROE of +0.12%. Regarding short-term risk, PEN is less volatile compared to INMD. This indicates lower risk in terms of short-term price fluctuations for PEN.Check INMD's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
PEN vs SIBN Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, SIBN has a market cap of 852M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while SIBN trades at $19.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas SIBN's P/E ratio is -56.50. In terms of profitability, PEN's ROE is +0.11%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, PEN is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for PEN.Check SIBN's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
PEN vs AVR Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, AVR has a market cap of 849.8M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while AVR trades at $8.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas AVR's P/E ratio is -4.51. In terms of profitability, PEN's ROE is +0.11%, compared to AVR's ROE of -0.78%. Regarding short-term risk, PEN is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for PEN.Check AVR's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
PEN vs CSII Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas CSII's P/E ratio is -20.83. In terms of profitability, PEN's ROE is +0.11%, compared to CSII's ROE of -0.14%. Regarding short-term risk, PEN is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for PEN.Check CSII's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
PEN vs AHCO Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, AHCO has a market cap of 787.8M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while AHCO trades at $5.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas AHCO's P/E ratio is 11.82. In terms of profitability, PEN's ROE is +0.11%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, PEN is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for PEN.Check AHCO's competition here
Varex Imaging Corporation (NASDAQ: VREX)
PEN vs VREX Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, VREX has a market cap of 778.9M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while VREX trades at $18.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas VREX's P/E ratio is 19.47. In terms of profitability, PEN's ROE is +0.11%, compared to VREX's ROE of +0.05%. Regarding short-term risk, PEN is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for PEN.Check VREX's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
PEN vs SSII Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, SSII has a market cap of 696.5M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while SSII trades at $3.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas SSII's P/E ratio is -67.88. In terms of profitability, PEN's ROE is +0.11%, compared to SSII's ROE of -0.27%. Regarding short-term risk, PEN is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for PEN.Check SSII's competition here
Surmodics, Inc. (NASDAQ: SRDX)
PEN vs SRDX Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas SRDX's P/E ratio is -34.66. In terms of profitability, PEN's ROE is +0.11%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, PEN is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for PEN.Check SRDX's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
PEN vs CTKB Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, CTKB has a market cap of 604.4M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while CTKB trades at $4.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas CTKB's P/E ratio is -24.79. In terms of profitability, PEN's ROE is +0.11%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, PEN is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for PEN.Check CTKB's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
PEN vs KIDS Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, KIDS has a market cap of 599M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while KIDS trades at $23.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas KIDS's P/E ratio is -19.76. In terms of profitability, PEN's ROE is +0.11%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, PEN is less volatile compared to KIDS. This indicates lower risk in terms of short-term price fluctuations for PEN.Check KIDS's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
PEN vs APEN Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas APEN's P/E ratio is -9.43. In terms of profitability, PEN's ROE is +0.11%, compared to APEN's ROE of -0.85%. Regarding short-term risk, PEN is less volatile compared to APEN. This indicates lower risk in terms of short-term price fluctuations for PEN.Check APEN's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
PEN vs DCTH Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, DCTH has a market cap of 564.1M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while DCTH trades at $16.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas DCTH's P/E ratio is 1634.00. In terms of profitability, PEN's ROE is +0.11%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, PEN is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for PEN.Check DCTH's competition here
ZimVie Inc. (NASDAQ: ZIMV)
PEN vs ZIMV Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, PEN's ROE is +0.11%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, PEN is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for PEN.Check ZIMV's competition here
Cerus Corporation (NASDAQ: CERS)
PEN vs CERS Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, CERS has a market cap of 534M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while CERS trades at $2.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas CERS's P/E ratio is -52.89. In terms of profitability, PEN's ROE is +0.11%, compared to CERS's ROE of -0.10%. Regarding short-term risk, PEN is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for PEN.Check CERS's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
PEN vs TCMD Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, TCMD has a market cap of 522.4M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while TCMD trades at $23.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas TCMD's P/E ratio is 21.44. In terms of profitability, PEN's ROE is +0.11%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, PEN is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for PEN.Check TCMD's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
PEN vs NPCE Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, NPCE has a market cap of 491.3M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while NPCE trades at $14.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas NPCE's P/E ratio is -25.28. In terms of profitability, PEN's ROE is +0.11%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, PEN is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for PEN.Check NPCE's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
PEN vs CLPT Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, CLPT has a market cap of 466.3M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while CLPT trades at $15.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas CLPT's P/E ratio is -13.18. In terms of profitability, PEN's ROE is +0.11%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, PEN is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for PEN.Check CLPT's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
PEN vs SGHT Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, SGHT has a market cap of 465.2M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while SGHT trades at $8.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas SGHT's P/E ratio is -15.27. In terms of profitability, PEN's ROE is +0.11%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, PEN is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for PEN.Check SGHT's competition here
Carlsmed, Inc. (NASDAQ: CARL)
PEN vs CARL Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, CARL has a market cap of 458.9M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while CARL trades at $16.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas CARL's P/E ratio is -11.80. In terms of profitability, PEN's ROE is +0.11%, compared to CARL's ROE of -0.38%. Regarding short-term risk, PEN is less volatile compared to CARL. This indicates lower risk in terms of short-term price fluctuations for PEN.Check CARL's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
PEN vs PACB Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, PACB has a market cap of 434.8M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while PACB trades at $1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas PACB's P/E ratio is -3.41. In terms of profitability, PEN's ROE is +0.11%, compared to PACB's ROE of -49.62%. Regarding short-term risk, PEN is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for PEN.Check PACB's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
PEN vs OFIX Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, OFIX has a market cap of 392.1M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while OFIX trades at $9.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas OFIX's P/E ratio is -6.32. In terms of profitability, PEN's ROE is +0.11%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, PEN is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for PEN.Check OFIX's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
PEN vs SENS Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, SENS has a market cap of 389.9M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while SENS trades at $9.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas SENS's P/E ratio is -4.18. In terms of profitability, PEN's ROE is +0.11%, compared to SENS's ROE of -1.66%. Regarding short-term risk, PEN is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for PEN.Check SENS's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
PEN vs CATX Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, CATX has a market cap of 353M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while CATX trades at $3.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas CATX's P/E ratio is -2.33. In terms of profitability, PEN's ROE is +0.11%, compared to CATX's ROE of -0.42%. Regarding short-term risk, PEN is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for PEN.Check CATX's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
PEN vs SMLR Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas SMLR's P/E ratio is 3.92. In terms of profitability, PEN's ROE is +0.11%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, PEN is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for PEN.Check SMLR's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
PEN vs TMCI Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, TMCI has a market cap of 301.7M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while TMCI trades at $4.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas TMCI's P/E ratio is -4.95. In terms of profitability, PEN's ROE is +0.11%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, PEN is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for PEN.Check TMCI's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
PEN vs TLSI Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, TLSI has a market cap of 297.4M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while TLSI trades at $4.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas TLSI's P/E ratio is -2.87. In terms of profitability, PEN's ROE is +0.11%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, PEN is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for PEN.Check TLSI's competition here
CapsoVision, Inc. (NASDAQ: CV)
PEN vs CV Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, CV has a market cap of 296.3M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while CV trades at $5.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas CV's P/E ratio is -2.37. In terms of profitability, PEN's ROE is +0.11%, compared to CV's ROE of -1.78%. Regarding short-term risk, PEN is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for PEN.Check CV's competition here
RxSight, Inc. (NASDAQ: RXST)
PEN vs RXST Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, RXST has a market cap of 291.8M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while RXST trades at $7.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas RXST's P/E ratio is -6.24. In terms of profitability, PEN's ROE is +0.11%, compared to RXST's ROE of -0.17%. Regarding short-term risk, PEN is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for PEN.Check RXST's competition here
Avita Medical Inc. (NASDAQ: RCEL)
PEN vs RCEL Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, RCEL has a market cap of 257.1M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while RCEL trades at $10.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas RCEL's P/E ratio is -7.19. In terms of profitability, PEN's ROE is +0.11%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, PEN is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for PEN.Check RCEL's competition here
Profound Medical Corp. (NASDAQ: PROF)
PEN vs PROF Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, PROF has a market cap of 248.9M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while PROF trades at $6.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas PROF's P/E ratio is -6.99. In terms of profitability, PEN's ROE is +0.11%, compared to PROF's ROE of -0.56%. Regarding short-term risk, PEN is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for PEN.Check PROF's competition here
Electromed, Inc. (AMEX: ELMD)
PEN vs ELMD Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, ELMD has a market cap of 245.3M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while ELMD trades at $29.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas ELMD's P/E ratio is 22.61. In terms of profitability, PEN's ROE is +0.11%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, PEN is less volatile compared to ELMD. This indicates lower risk in terms of short-term price fluctuations for PEN.Check ELMD's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
PEN vs MGRM Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas MGRM's P/E ratio is -12.00. In terms of profitability, PEN's ROE is +0.11%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, PEN is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for PEN.Check MGRM's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
PEN vs INFU Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, INFU has a market cap of 242.6M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while INFU trades at $12.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas INFU's P/E ratio is 29.32. In terms of profitability, PEN's ROE is +0.11%, compared to INFU's ROE of +0.15%. Regarding short-term risk, PEN is less volatile compared to INFU. This indicates lower risk in terms of short-term price fluctuations for PEN.Check INFU's competition here
Nevro Corp. (NYSE: NVRO)
PEN vs NVRO Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas NVRO's P/E ratio is -1.91. In terms of profitability, PEN's ROE is +0.11%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, PEN is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for PEN.Check NVRO's competition here
Neuronetics, Inc. (NASDAQ: STIM)
PEN vs STIM Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, STIM has a market cap of 204.6M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while STIM trades at $2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas STIM's P/E ratio is -6.68. In terms of profitability, PEN's ROE is +0.11%, compared to STIM's ROE of -1.51%. Regarding short-term risk, PEN is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for PEN.Check STIM's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
PEN vs BSGM Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas BSGM's P/E ratio is -5.81. In terms of profitability, PEN's ROE is +0.11%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, PEN is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for PEN.Check BSGM's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
PEN vs LUCD Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, LUCD has a market cap of 189.1M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while LUCD trades at $0.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas LUCD's P/E ratio is -2.68. In terms of profitability, PEN's ROE is +0.11%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, PEN is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for PEN.Check LUCD's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
PEN vs MDGS Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas MDGS's P/E ratio is -0.27. In terms of profitability, PEN's ROE is +0.11%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, PEN is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for PEN.Check MDGS's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
PEN vs QIPT Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas QIPT's P/E ratio is -15.87. In terms of profitability, PEN's ROE is +0.11%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, PEN is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for PEN.Check QIPT's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
PEN vs FOCL Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, FOCL has a market cap of 161.5M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while FOCL trades at $4.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas FOCL's P/E ratio is -4.17. In terms of profitability, PEN's ROE is +0.11%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, PEN is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for PEN.Check FOCL's competition here
Quantum-Si incorporated (NASDAQ: QSI)
PEN vs QSI Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, QSI has a market cap of 154.3M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while QSI trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas QSI's P/E ratio is -1.70. In terms of profitability, PEN's ROE is +0.11%, compared to QSI's ROE of -0.47%. Regarding short-term risk, PEN is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for PEN.Check QSI's competition here
Inogen, Inc. (NASDAQ: INGN)
PEN vs INGN Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, INGN has a market cap of 148.9M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while INGN trades at $5.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas INGN's P/E ratio is -6.04. In terms of profitability, PEN's ROE is +0.11%, compared to INGN's ROE of -0.13%. Regarding short-term risk, PEN is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for PEN.Check INGN's competition here
Quanterix Corporation (NASDAQ: QTRX)
PEN vs QTRX Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, QTRX has a market cap of 124.4M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while QTRX trades at $2.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas QTRX's P/E ratio is -1.04. In terms of profitability, PEN's ROE is +0.11%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, PEN is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for PEN.Check QTRX's competition here
iCAD, Inc. (NASDAQ: ICAD)
PEN vs ICAD Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas ICAD's P/E ratio is -20.37. In terms of profitability, PEN's ROE is +0.11%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, PEN is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for PEN.Check ICAD's competition here
LENSAR Inc (NASDAQ: LNSR)
PEN vs LNSR Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, LNSR has a market cap of 101.9M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while LNSR trades at $8.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas LNSR's P/E ratio is 8.47. In terms of profitability, PEN's ROE is +0.11%, compared to LNSR's ROE of +103.80%. Regarding short-term risk, PEN is less volatile compared to LNSR. This indicates lower risk in terms of short-term price fluctuations for PEN.Check LNSR's competition here
Pulmonx Corporation (NASDAQ: LUNG)
PEN vs LUNG Comparison September 2026
Penumbra, Inc. (NYSE: PEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PEN stands at 12.7B. In comparison, LUNG has a market cap of 100.5M. Regarding current trading prices, PEN is priced at $321.68 on the NYSE, while LUNG trades at $2.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PEN currently has a P/E ratio of 84.03, whereas LUNG's P/E ratio is -2.05. In terms of profitability, PEN's ROE is +0.11%, compared to LUNG's ROE of -0.97%. Regarding short-term risk, PEN is less volatile compared to LUNG. This indicates lower risk in terms of short-term price fluctuations for PEN.Check LUNG's competition here